|Awarded On||November 19, 2014|
|Title||Targeting an Elusive Foe: Development of K-Ras Inhibitors|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Alemayehu Gorfe|
|Cancer Sites||Bladder, Colorectal, Lung and Bronchus, Pancreas, Stomach|
The United States National Cancer Institute estimates that there will be close to 1.7 million new cancer cases and 585,720 cancer-related deaths in 2014. Activating mutations of a key enzyme in humans, called K-Ras, are known to occur in about 25% of all human cancers. Combining these two statistics, we estimate that about 400,000 US citizens will be affected by one or another form of K-Ras-related cancers this year alone.
Currently, there are no drugs that can directly act on mutated K-Ras to stop its cancer-causing activities. As a result, K-Ras-related cancers remain untreatable, including some of the deadliest such as pancreatic cancer. In fact, the prognosis of K-Ras-associated cancers...